The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis

Simple item page
dc.contributor.authorYarkan Tuğsal H.
dc.contributor.authorKenar G.
dc.contributor.authorCan G.
dc.contributor.authorÇapar S.
dc.contributor.authorZengin B.
dc.contributor.authorAkar S.
dc.contributor.authorDalkiliç E.
dc.contributor.authorŞenel S.
dc.contributor.authorKoca S.S.
dc.contributor.authorGöker B.
dc.contributor.authorYazici A.
dc.contributor.authorİnanç N.
dc.contributor.authorEllidokuz H.
dc.contributor.authorAkkoç N.
dc.contributor.authorÖnen F.
dc.date.accessioned2024-07-22T08:03:15Z
dc.date.available2024-07-22T08:03:15Z
dc.date.issued2023
dc.description.abstractBackground/aim: To investigate the impact of smoking on disease activity, treatment retention, and response in patients with ankylosing spondylitis (AS) treated with their first tumor necrosis factor-α inhibitor (TNFi). Materials and methods: AS patients who started their first TNFi treatment for the active axial disease (BASDAI ≥ 4) from TURKBIO Registry were included. Treatment response of smoker (current and ex-smokers) and nonsmoker (never smoker) patients were primarily evaluated as achievement of BASDAI50 or improvement in BASDAI at least 20 mm at 3 months and 6 months compared to baseline. Results: There were 322 patients with AS (60% male, 59% smoker, mean age: 38.3 years). The median follow-up time was 2.8 years (Q1– Q3: 1.3–3.8), and disease duration was 3.5 years (Q1–Q3: 0.7–8.2). Smokers had male predominance (p < 0.001), lower ESR (p = 0.03), higher BASDAI (p = 0.02), BASFI (p = 0.05), HAQ-AS (p = 0.007), and ASDAS-CRP (p = 0.04) compared with nonsmokers at baseline. In the multivariate analysis, male gender [OR 2.7 (95%CI 1.4–5), p = 0.002], and concomitant conventional synthetic disease-modifying antirheumatic drug use [OR 2.4 (95%CI 1.1–5.2), p = 0.03] were associated with better treatment response. There was an association of male gender [HR 2.4 (95%CI 1.6–3.7), p < 0.001], older age (≥30years) [HR 1.8 (95%CI 1.1–2.8), p = 0.01], and response to treatment [HR 1.8 (95%CI 1.2–2.9), p = 0.008] with better treatment retention. No impact of smoking status was found on treatment retention and response in univariate and multivariate analyses. Conclusion: This study suggested that smoking was associated with poorer patient-reported outcomes in biologic naïve AS patients initiating their first TNFi treatment, but it had no impact on the TNFi treatment response and retention rate. © TÜBİTAK.
dc.identifier.DOI-ID10.55730/1300-0144.5661
dc.identifier.issn13000144
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12176
dc.language.isoEnglish
dc.publisherTurkiye Klinikleri
dc.rightsAll Open Access; Bronze Open Access
dc.subjectAdult
dc.subjectAntirheumatic Agents
dc.subjectFemale
dc.subjectHumans
dc.subjectImmunologic Factors
dc.subjectMale
dc.subjectSeverity of Illness Index
dc.subjectSmoking
dc.subjectSpondylitis, Ankylosing
dc.subjectTreatment Outcome
dc.subjectTumor Necrosis Factor-alpha
dc.subjectadalimumab
dc.subjectC reactive protein
dc.subjectcertolizumab pegol
dc.subjectinfliximab
dc.subjectmethotrexate
dc.subjectsalazosulfapyridine
dc.subjecttumor necrosis factor inhibitor
dc.subjectantirheumatic agent
dc.subjectimmunologic factor
dc.subjecttumor necrosis factor
dc.subjectadult
dc.subjectankylosing spondylitis
dc.subjectAnkylosing Spondylitis Disease Activity Score
dc.subjectAnkylosing Spondylitis Quality of Life questionnaire
dc.subjectArticle
dc.subjectBath ankylosing spondylitis disease activity index
dc.subjectbody mass
dc.subjectcohort analysis
dc.subjectcontrolled study
dc.subjectdisease activity
dc.subjectdisease duration
dc.subjecterythrocyte sedimentation rate
dc.subjectex-smoker
dc.subjectfemale
dc.subjectHealth Assessment Questionnaire
dc.subjecthuman
dc.subjectmale
dc.subjectobservational study
dc.subjectquality of life
dc.subjectsmoking
dc.subjecttreatment response
dc.subjectankylosing spondylitis
dc.subjectepidemiology
dc.subjectseverity of illness index
dc.subjectsmoking
dc.subjecttreatment outcome
dc.titleThe impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis
dc.typeArticle

Files

Collections

Scopus Koleksiyonu